Sompraz%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520hp

# Sompraz HP ## Overview Sompraz HP is a fixed-dose combination product containing lansoprazole, amoxicillin, and clarithromycin. Lansoprazole is a proton pump inhibitor (PPI), while amoxicillin and clarithromycin are antibiotics. ## Primary Indications * **Helicobacter pylori (H. pylori) eradication:** Used as part of a therapeutic regimen to eradicate H. pylori infection in patients with peptic ulcer disease or for those seeking relief from H. pylori-related symptoms. ## Adult Dosing * **Standard Regimen:** Typically administered as one capsule (containing lansoprazole 30 mg, amoxicillin 1 gram, and clarithromycin 500 mg) taken orally twice daily for 7 days. * **Specific Dosing:** Dosing may vary based on local resistance patterns and clinical guidelines. Always consult current prescribing information or institutional protocols. ## Pediatric Dosing * **Established pediatric dosing is not readily available for this specific combination product.** Pediatric H. pylori treatment regimens are individualized and depend on age, weight, local resistance patterns, and patient tolerance. Consult pediatric gastroenterology or infectious disease guidelines for appropriate pediatric regimens. ## Dose Adjustments * **Renal Impairment:** No specific dose adjustment for the combination product is typically recommended, although individual components may require adjustment in severe renal impairment. Amoxicillin elimination is significantly reduced in renal failure. Clarithromycin accumulation can occur in renal impairment. * **Hepatic Impairment:** Lansoprazole and clarithromycin may require dose adjustments in severe hepatic impairment. Consult specific product monographs. ## Contraindications * Hypersensitivity to lansoprazole, amoxicillin, clarithromycin, other macrolides, or penicillins. * History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use. * Concomitant use with cisapride, ergotamine, ergonovine, methylergonovine, pimozide, or potentially other drugs that are CYP3A4 substrates with narrow therapeutic windows. * Severe renal impairment when used with colchicine. ## Adverse Effects * **Common:** Diarrhea, nausea, vomiting, abdominal pain, headache, taste disturbance, rash. * **Serious:** Clostridioides difficile-associated diarrhea, severe allergic reactions (anaphylaxis, Stevens-Johnson syndrome), liver dysfunction, QT prolongation, tendon rupture (fluoroquinolones, not directly related but general antibiotic class caution), potential for antibiotic resistance with prolonged use. ## Key Drug Interactions * **Lansoprazole:** May decrease the absorption of drugs requiring acidic environments (e.g., ketoconazole, itraconazole, iron salts). May increase levels of drugs metabolized by CYP2C19 (e.g., clopidogrel - though the clinical significance is debated). * **Clarithromycin:** Potent inhibitor of CYP3A4. Can increase serum concentrations of numerous drugs, including statins (risk of myopathy), warfarin, some anticonvulsants, some antiretrovirals, and colchicine. Avoid co-administration with cisapride, pimozide, ergot alkaloids. * **Amoxicillin:** May interfere with the effectiveness of oral contraceptives. Probenecid can decrease renal excretion of amoxicillin. ## Monitoring * **Treatment Efficacy:** H. pylori eradication should ideally be confirmed by urea breath test, stool antigen test, or biopsy after completion of therapy. * **Adverse Effects:** Monitor for signs of C. difficile infection, hypersensitivity reactions, liver function abnormalities, and gastrointestinal disturbances. * **Drug Interactions:** Assess for potential interactions, especially with clarithromycin's CYP3A4 inhibition. ## Clinical Pearls * This is a triple therapy regimen designed for H. pylori eradication and should be completed as prescribed. * Ensure patients are not allergic to any component of the combination. * Advise patients to take the medication with food or on an empty stomach as directed by labeling or institutional protocol, noting that PPI absorption may be affected by food. * Antibiotic resistance is a significant concern for H. pylori treatment; this regimen should be used judiciously and according to established guidelines. * Consider local resistance patterns when selecting H. pylori eradication regimens. *** **Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information, institutional guidelines, and relevant literature before making treatment decisions.